Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
As three Asco presentations confirm the Her2-targeting agent's potency, Daiichi Sankyo and Astrazeneca lay out an ambitious development programme.
The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
Clinical data are expected soon from Novo Nordisk, Bayer and Sanofi, while Roche and Gilead take aim at ulcerative colitis.
Astra and Merck & Co present mixed small-cell lung cancer data, while Innovent, Xencor, Alphamab and Alligator bang the drum for CTLA-4.
The upcoming cancer meeting shows Roche and Bristol trying to catch up with Merck & Co, with some read-across to biotech.